Idera Pharmaceuticals is a clinical stage biotechnology company with expertise in discovering, developing and commercializing novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. Idera is focused on harnessing the potential of our proprietary technology to treat genetically defined forms of B-cell lymphomas and rare autoimmune diseases. Learn More
Clinical Trials
Idera is advancing to the clinic in genetically defined forms of B-cell lymphoma: activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) and Waldenström’s macroglobulinemia.
Key Presentations and Publications
View selected scientific presentations and publications highlighting Idera’s leadership in the development of nucleic acid therapeutics.
“TLR structure” by The cat, used under GNU Free Documentation License / Cropped and colored background from original.
